Elevation Oncology, Inc. announced on March 25, 2025, that it will present preclinical data for its novel HER3 antibody-drug conjugate (ADC), EO-1022, at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data will be featured in a late-breaking poster presentation.
EO-1022 is an ADC comprising seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody, site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4. This design leverages advanced site-specific conjugation technology licensed from Synaffix B.V.
The company is developing EO-1022 for the treatment of solid tumors that express HER3, including breast cancer and non-small cell lung cancer. Elevation Oncology expects to file an Investigational New Drug (IND) application for EO-1022 in 2026, marking its progression towards clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.